Exco InTouch's eDiary Technologies to be Used in Pfizer's Virtual Clinical Trial
In order to support the success of this patient-centered, field-based clinical research, Pfizer required a mobile technology platform offering an ease-of-use interface that provided accessibility particularly for older patients. With an estimated five billion cellphone users worldwide, cell phones make an ideal and accessible platform for patient engagement in clinical trials. As part of the new approach piloted by the REMOTE study, patients will be empowered to participate remotely in the screening process through trials via the internet, participate in trials that due to location may not have previously been possible, actively manage their own trial, and report results directly to a trial. As a result, researchers expect to save time and obtain more reliable, higher quality data through increased patient compliance and engagement, lower withdrawal rates and real-time data collection. The new approach will also eliminate the costs associated with the management and co-ordination of running multiple clinical sites.
Exco InTouch offers three validated ePRO solutions, spanning simple diaries to the most complex clinical assessments, all of which can be customized to meet the requirements of individual trials.These technologies have been developed with an intuitive design to provide easy navigation that enhances the user experience, while positively impacting on-going compliance from patients, regardless of their age and logistics.Where specific and targeted data collection is required, patients can complete diary questionnaires via a series of text messages sent to their own cellphone.If a response is not received by the patient within a certain timeframe, a text message reminder can be automatically sent in order to prompt a response. The ability to capture patient data in “real-time” means that investigator site staff can be alerted to abnormal patient data and react to ensure patient safety.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025